- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PYK2 promotes HER2-positive breast cancer invasion ; volume:38 ; number:1 ; day:22 ; month:5 ; year:2019 ; pages:1-14 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (22.5.2019), 1-14, 12.2019
- Urheber
-
Al-Juboori, Shaymaa IK
Vadakekolathu, Jayakumar
Idri, Sarra
Wagner, Sarah
Zafeiris, Dimitrios
Pearson, Joshua RD
Almshayakhchi, Rukaia
Caraglia, Michele
Desiderio, Vincenzo
Miles, Amanda K.
Boocock, David J.
Ball, Graham R.
Regad, Tarik
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-019-1221-0
- URN
-
urn:nbn:de:101:1-2019111613021234533863
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Al-Juboori, Shaymaa IK
- Vadakekolathu, Jayakumar
- Idri, Sarra
- Wagner, Sarah
- Zafeiris, Dimitrios
- Pearson, Joshua RD
- Almshayakhchi, Rukaia
- Caraglia, Michele
- Desiderio, Vincenzo
- Miles, Amanda K.
- Boocock, David J.
- Ball, Graham R.
- Regad, Tarik
- SpringerLink (Online service)
Ähnliche Objekte (12)
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers